A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Status:
RECRUITING
Trial end date:
2028-07-31
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the efficacy and safety of ESG401 in patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer.